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SUPPLEMENTARY METHODS
Chemistry General Experimental
Melting points were obtained on OptiMelt Automated Melting Point System with Digital Image Processing
Technology and are uncorrected. 1 H NMR and 13 C NMR were recorded at the Nuclear Magnetic Resonance
Facility within the Mark Wainwright Analytical Centre at The University of New South Wales on a Bruker
Avance III 300 (300 MHz), Bruker DPX 300 (300 MHz), Bruker Avance III 400 (400 MHz), Bruker Avance III 500 (500 MHz) or Bruker Avance III 600 (600 MHz), with data acquired and processed using TopSpin 3.0 software. Chemical shifts are expressed in parts per million (ppm) on the δ scale. Chemical shifts in CDCl3
were referenced relative to CHCl3 (7.26 ppm) for 1 H NMR and CHCl3 (77.16 ppm) for 13 C NMR. 1 Infrared spectra were obtained on a ThermoNicolet Avatar 370 FT-IR spectrometer and are reported in wavenumbers (cm -1 ). Spectra were recorded from thin films using NaCl plates. HRMS were performed at the Bioanalytical
Mass Spectrometry Facility within the Mark Wainwright Analytical Centre at The University of New South
Wales on an Orbitrap LTQ XL (Thermo Fisher Scientific, San Jose, Ca, USA) ion trap mass spectrometer using a nanospray (nano-electrospray) ionization source to generate ions from the analyte in solution. The instrument was calibrated with a standard calibration solution (as outlined in the instrument manual) on the day of analysis using direct infusion with the nanospray source. The instrument conditions were optimized for sensitivity on each compound of interest using LC tune software. The analysis was carried out in positive ion mode using the orbitrap FTMS analyser at a resolution of 100000. Samples, 5 µL, (1 µg/mL in methanol or acetonitrile), were injected into a glass needle and inserted into the nanospray source. Ions generated were 0  95  5  2  95  5  20  0  100  22  0  100  22  95  5  30 95 5 Unless otherwise stated all reactions were performed in flame dried glassware under an atmosphere of dry argon. Reaction temperatures refer to the external bath temperature. Concentration of solvents was performed under reduced pressure on a rotary evaporator after which, residual solvent was removed under high vacuum (~0.1 mm/Hg).
Time (min) Solvent A (%) Solvent B (%)
Reagents and solvents were purchased from commercial sources and used without further purification, unless stated below. Reagents and solvents used in reactions were purified according to well established procedures. 1,2 In particular, tetrahydrofuran (THF) was freshly distilled from sodium and benzophenone under an inert atmosphere of argon. N,N-Dimethylformamide (DMF) was dried sequentially over three batches of 4Ǻ molecular sieves (3 × 24 h), before finally being stored over a fourth batch of 4Ǻ molecular sieves, under argon.
To remove residual N,N-dimethylamine from DMF, the solvent was evacuated (~0.1 mm/Hg) for at least 30 min prior to use. Methanol was distilled from magnesium and stored over 3Ǻ molecular sieves, under argon.
Dichloromethane was distilled from calcium hydride and stored over 4Ǻ molecular sieves. Petroleum spirit used for chromatography was of the fraction 40-60°C.
Analytical thin layer chromatography was conducted on Merck, aluminium-backed silica plates 60 F254 or silica gel 60 RP-C18 F254 plates and visualised using UV light and stained with a dip of either a potassium permanganate, vanillin or phosphomolybdic acid. Flash chromatography was routinely performed using Grace Davison Discovery Sciences, Davisil LC60A 40 -63 micron silica gel, following published guidelines. 3 Solvent was eluted using a Thomson SINGLE StEP pump at the flow rate recommended by the manufacturer (Thomson Instrument Company, Oceanside, Ca, USA). Deactivated silica gel was prepared by washing a column packed with silica gel with neat triethylamine (5 column volumes). After drying, the column was washed with petroleum spirit to remove any residual triethylamine. 
Synthesis and Characterisation
General Procedures for the Synthesis of S4, S5 and S6
(1) A solution of piperazine (1 equiv.), benzotrifluoride (1 equiv.) and sodium bicarbonate (2.5 equiv.) in THF (1 M) was heated at reflux for 16 hours. The solution was allowed to cool to room temperature and the reaction solution was filtered through a short pad of Celite, eluting with ethyl acetate. The solvent was removed under reduced pressure to afford the product, which was of sufficient purity to use in the next step.
On occasion when the crude product was impure it could be purified by flash chromatography on deactivated silica gel to afford the product. room temperature. The solution was heated at reflux for two hours. The solution was allowed to cool to room temperature then filtered through a short pad of Celite, eluting with ethyl acetate. The solvent was removed under reduced pressure. The residue was diluted with water and extracted with ethyl acetate (× 3). The organic extracts were combined and dried (Na2SO4). The solvent was removed under reduced pressure to afford the product as a white solid, which was of sufficient purity to use in the next step. 
2-(4-Methylpiperazin-1-yl)-5-(trifluoromethyl)aniline (S4) 4
General Procedures for the Synthesis of 2, 3 and SPHINX31
A solution of trimethylaluminium in toluene (2 M, 3 equiv.) was added dropwise to a solution of aniline S4, S5
or S6 (1 equiv.) in dichloromethane (0.5 M) at room temperature. The solution was stirred at room temperature for 1 hour after which, a solution of methyl 5-(pyridin-4-yl)furan-2-carboxylate 5 (1 equiv.) in dichloromethane (1 M) was added dropwise at room temperature. The reaction solution stirred at room temperature for an additional 16 hours. To quench the reaction saturated aqueous Rochelle's salt solution was added dropwise at room temperature and the solution allowed to stir at room temperature for a further 15 minutes. The mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane (× 3).
The organic extracts were combined and washed with water and brine, then dried (Na2SO4). The solvent was removed under reduced pressure and the crude material was purified by flash chromatography on deactivated silica gel to afford the product. glycerol were incubated with compound 1 and SPHINX31 at 1 mM concentration, prior to setting up the sitting-drop crystallization at 4 ˚C. For SRPK1-compound 1 complex, the crystals were obtained using 20% PEG-6000, 13% Ethylene glycol, 0.1M Tris pH 9.5 and 0.1M Calcium chloride, while the co-crystals of SRPK1-SPHINX31 complex grew in 22%
broad-molecular-weight PEG smears and 0.1 M citrate, pH 5.5. 6 For SRPK2, the recombinant protein was purified using the similar procedure as that used for purification of SRPK1. The pure SRPK2 protein in 50 mM HEPES, pH 7.5, 500 mM NaCl and 5% glycerol was mixed with 1 mM compound 1, and the complex was crystallized at 4 ˚C using the reservoir solution containing 1 M ammonium sulfate and 0.1 M acetate, pH 5.25.
All crystals were cryo-protected with the mother liquor supplemented with 20% ethylene glycol before flash-frozen in liquid nitrogen. Diffraction data collected at Diamond Light Source using X-ray at 0.9795 Å wavelength were processed and scaled with XDS 7 and Scala 8 or Aimless 9 , respectively. Initial structure solutions were obtained with molecular replacement method using Phaser and the coordinates of SRPK1 (pdb id: 1WAK) 10 or SRPK2 (pdb id: 2X7G). Iterative cycles of model building alternated with structure refinement were performed in COOT 11 and REFMAC 12 , respectively. The geometry of the final model was verified by MOLPROBITY. 13 Data collection and refinement statistics are summarized in Supplementary Table 2 .
Coordinates and accession codes:
Coordinates have been deposited with the Protein Data Bank with the designation 'for immediate release upon publication'. The Accession Codes are as follows:
SRPK1.1 pdb id = 5MXX SRPK1.SPHINX31 pdb id = 5MY8 SRPK2.1 pdb id = 5MYV
Biology In Vitro Kinase Screening Assay
Candidate compounds were tested for SRPK1 inhibition using a Kinase-Glo assay Protein studies -immunoblotting and immunoprecipitation.
Whole cell lysate (nuclear and cytoplasmic) protein extracts were prepared as described. HEPES (titrated to pH 7.2 with KOH). Pipette resistance typically ranged from 1.5-3.5 MΩ and ∼70-80% series resistance could be compensated. Data were acquired using an Axopatch 1D amplifier and a CV-4 1/100 headstage and digitised using a Digidata 1200B interface (Axon Instruments, USA). Voltage commands were generated and data acquired using Clampex 8 (Axon Instruments, USA) and data were stored on the hard-disk of a Viglen computer for off-line analysis. Data were digitized at 10kHz with an appropriate bandwidth set on the amplifier. Compounds were applied using a home-built rapid solution exchange device capable of changing superfusate in <1 second. Large scale screening was undertaken by Essen Biosciences.
HERG assay
T m -Shift assay
Thermal melting experiments were carried out using a Stratagene Mx3005p Real Time PCR machine (Agilent Technologies). Proteins at 2 µM concentration buffered in 10 mM HEPES, pH 7.5, 500 mM NaCl Were mixed with compounds at a final concentration of 12.5 µM (final DMSO concentration was 0.02%). Experiments were performed in triplicate and data were analysed as previously described.
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Isothermal Titration Calorimetry (ITC)
The ITC experiment was performed at 30 ˚C using Nano-ITC (TA instrument). The protein in 50mM HEPES, pH 7.5, 500mM NaCl, 0.5mM TCEP, 5% glycerol at 50 µM was titrated into 6 µM SPHINX31. The heated of binding were analyzed, and the data were fitted to an independent binding model using NanoAnalyze program (TA instrument), from which the thermodynamic parameters were calculated (∆G = ∆H -T∆S = -RTlnKB, where ∆G, ∆H and ∆S are the changes in free energy, enthalpy and entropy of binding, respectively).
Thermodynamic parameters and binding constants are given in Supplemental Table 2 .
Primary human retinal epithelial cell culture
Primary human RPE isolations were performed on human donor globes obtained within 24 
Pharmacological inhibitor treatments.
Cells at ~70% confluence were serum starved for 24 h and treated with inhibitors at concentration noted. To determine pSRSF1 levels, cells were pre-treated with SPHINX31
for 1 hr then treated with TNF α (50 ng/ml) for 30 mins. For VEGF immunoblots in PC-3 cells, cells were treated with inhibitors for 24 h, washed off and lysed 24 h after washing.
Enzyme-linked immunosorbent assay (ELISA).
10 µg/ml VEGF 165 
Laser lesion induction protocol
Six to eight week-old female C57/B6 mice (Charles River) were anaesthetized with an intraperitoneal injection of a mixture of 50mg/kg ketamine and 0.5mg/kg medetomidine.
The pupils were dilated with 5% phenylephrine hydrochloride and 1% tropicamide. Four photocoagulation lesions were delivered with a Micron IV laser photocoagulation instrument (Phoenix Instruments) (450mW, 130ms, 75 µm) between the retinal vessels in a peripapillary distribution at a distance of 1-2 disc-diameters from the optic nerve in each eye. Only laser lesions with a sub-retinal bubble at the time of treatment were included in the study. Immediately following laser photocoagulation the animals received topical eye drops twice daily (10 µl) as previously described. 14 On day 7 and 14 animals were anaesthetized and pupils dilated as above, and received 100 µl of 10 mg/ml sodium fluorescein in PBS i.p. and retinae imaged using the Micron IV. Animals were culled on either day 7 (protein extraction) or day 14 (FFA) and eyes were either unfixed for retinal dissection and protein extraction, or fixed and enucleated and choroids stained and examined. Choroidal lesions were imaged and areas traced by a masked observer, lesions area was quantified using Image J.
Mass Spectrometry
Compounds were serially diluted in water (initial stock dissolved in DMSO) from 5 µg/ml to 0 µg/ml, spiked with an internal standard 1 µg/ml compound 3 to account for any loss of samples during preparation and analysed. The chromatograms produced clear peaks at the expected molecular weights. The area under the peaks were integrated and plotted against concentration to confirm a linear response was observed. After a single topical administration mice were killed at time points 1, 4, 8, and 24 hours. Samples, the analyte and control treated samples, were homogenized and proteins were precipitated out of the samples with an equal volume (300 µl) acetonitrile. An internal standard of 1 µg/ml compound 3 was added to samples to account for any loss of samples during preparation.
The solutions of 50% sample and 50% acetonitrile and 1 µg/ml 3 were centrifuged for 15 minutes at 4°C to pellet the proteins and the supernatant taken for analysis. Solutions min 90% A. SPHINX31 eluted at 3 min and 3 at 1.9 min. Peaks occurring at these times in the SIM chromatograms for each compound were integrated using Varian Integration software and used to quantify SPHINX31.
For quantification of SPHINX31 in mouse plasma stability, metabolite and liver microsome stability assays, mass spectrometry was performed at O2H, India, using an Agilent 6410
series Triple Quad LC-MS with a Waters X Bridge C18 HPLC column (4.6 x 50 mm, 5 µM).
Detection was achieved by positive ion electrospray (ESI+) mass spectrometry using a Agilent 6410 series Triple Quad LC-MS spectrometer in multiple ion monitoring (MRM).
For SPHINX31 Q1 = 508.6, Q2 = 420-520. Mass spectrometer settings were as follows: 
Statistical Analyses
If not indicated otherwise, data are shown as mean ± SEM. All data, graphs and statistical analyses were calculated with Microsoft Excel (Microsoft Office Software), GraphPad Prism (GraphPad Software Inc.) and Image J. All results were considered statistically significant at p<0.05 (*), p<0.01 (**) and p<0.001 (***).
Constructs and protein expression and purification
cDNAs encoding several human splicing kinases [SRPK1-2, MSSK1; CLK1-4; DYRK1A-2, PRPF4B; PIM1-2] were obtained from synthetic sources and used as templates to amplify kinase domain-containing sequences and further sub-cloned into different expression vectors, using ligation independent cloning. (GE Healthcare) pre-equilibrated into GF Buffer (50 mM HEPES pH7.5, 300 mM NaCl, 5%
glycerol, and 0.5 mM TCEP). The resulting pure protein was stored at −80 °C in 50 mM HEPES, pH 7.5, 300 mM NaCl, 0.5 mM TCEP and 5% glycerol. 
